CN111518751A - Method for in vitro activating adipose-derived stem cells to convert adipose-derived stem cells into protochondrocytic cells - Google Patents
Method for in vitro activating adipose-derived stem cells to convert adipose-derived stem cells into protochondrocytic cells Download PDFInfo
- Publication number
- CN111518751A CN111518751A CN201911143935.4A CN201911143935A CN111518751A CN 111518751 A CN111518751 A CN 111518751A CN 201911143935 A CN201911143935 A CN 201911143935A CN 111518751 A CN111518751 A CN 111518751A
- Authority
- CN
- China
- Prior art keywords
- adipose
- derived stem
- stem cells
- placing
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a method for activating adipose-derived stem cells to convert into protochondrocytes in vitro, which comprises the following steps: preparing a DMEM medium, wherein the proportion of the DMEM medium is 1% fetal calf serum, 10ng/ml TGF-beta, 100ng/ml BMP-6, 6.25 mu g/ml insulin, 0.1 mu mol/L dexamethasone, 6.25 mu g/ml transferrin and 50 mu mol/L ascorbic acid phosphate; placing the adipose-derived stem cells forming the micelles in a DMEM culture medium for culturing; injecting the adipose-derived stem cells cultured for 7-9 days into joint cavity to transform into protochondrocytes. The invention has the advantages of time saving, simple process control and low rejection of the generated chondrocytes.
Description
Technical Field
The invention relates to the field of medicines, in particular to a method for activating adipose-derived stem cells to convert into protochondrocytes in vitro.
Background
Bone marrow mesenchymal stem cells (BMSCs) among Mesenchymal Stem Cells (MSCs) which have been used more so far are hot spots of research and widely applied to scientific research. In 2001, Zuk et al isolated 1 st from liposuction extracted adipose tissue suspensions to obtain multipotential stem cells. Adipose-derived stem cells (ASCs) are superior to BMSCs in that they are easily obtained, have a large quantity of materials, can be repeatedly obtained, and can proliferate rapidly. Meanwhile, ASCs can be differentiated into chondrocytes, osteoblasts, adipocytes, nerve cells, etc., respectively, in a specific microenvironment. Therefore, the ASCs are expected to become good tissue engineering seed cells.
The major problems are that (1) the currently known ASCs have a plurality of surface molecules, but most of the ASCs are crossed with other mesenchymal stem cells, and have no specific surface antigen, so that the combined screening by selecting the high-specificity surface marker antigen is difficult; (2) although many laboratories have attempted to induce differentiation of ASCs into cartilage tissue using different materials and techniques, none have avoided the consequences of inflammatory reactions between cartilage tissues; (3) in many experiments, the phenomenon of hypertrophy and hyperplasia of chondrocytes appears in the cultured chondrocytes in the later experiment results; (4) at present, the differentiation of the ASCs into the chondrocytes is basically realized by constructing a 3D model, but the clinical practicability of the method is not high.
Disclosure of Invention
In view of the above, the present invention provides a method for activating the transformation of adipose derived stem cells into chondroblasts in vitro.
The purpose of the invention is realized by adopting the following technical scheme:
a method for activating the transformation of adipose-derived stem cells into protochondrocytes in vitro, comprising the following steps:
preparing a DMEM medium, wherein the proportion of the DMEM medium is 1% fetal calf serum, 10ng/ml TGF-beta, 100ng/ml BMP-6, 6.25 mu g/ml insulin, 0.1 mu mol/L dexamethasone, 6.25 mu g/ml transferrin and 50 mu mol/L ascorbic acid phosphate;
placing the adipose-derived stem cells forming the micelles in a DMEM culture medium for culturing;
injecting the adipose-derived stem cells cultured for 7-9 days into joint cavity to transform into protochondrocytes.
Optionally, the preparation steps of the adipose-derived stem cells are as follows:
cleaning adipose tissues by using a buffer solution to remove residual blood and tissue fragments, cutting the cleaned adipose tissues into small pieces, digesting the small pieces in a shaking box for 20-60 min, standing the small pieces until the small pieces are layered, sucking upper layer adipose cell fluid, placing the adipose cell fluid in a box body at the temperature of 0-5 ℃ for culturing for 1-2 hours, sealing and centrifugally separating the box body, and removing supernatant to prepare adipose stem cell suspension;
placing the adipose-derived stem cell suspension in a cell activation medium for activation culture for 10-20 hours so as to obtain preliminarily expanded adipose-derived stem cells;
placing the adipose-derived stem cells into at least one cell culture medium and adding an activating reagent to perform adipose-derived stem cell suspension culture for 12-15 hours so as to obtain activated adipose-derived stem cells;
taking out the activated adipose-derived stem cells from the culture medium, adding normal saline, cleaning, adding enzyme solution for digestion, and culturing for three to six generations after the adipose-derived stem cells grow to 80-90% and are fused;
and naturally placing the culture solution after passage for 3-5 hours to obtain the micelle adipose-derived stem cells.
Alternatively, adipose-derived stem cells cultured for 8 days are injected into the joint cavity and transformed into protochondrocytes.
Optionally, the adipose-derived stem cells are cultured for five generations after 80% -90% of the adipose-derived stem cells are fused.
Optionally, the cell activation medium is a serum-free lymphocyte culture medium added with interleukin-2 and saperin.
Optionally, the cell activation medium is supplemented with mammalian serum.
Optionally, the mammalian serum is mammalian fetal serum.
Optionally, the activating agent is a calcium ionophore.
Optionally, the calcium ionophore is selected from a23187 or ionomycin.
The invention provides a method for activating adipose-derived stem cells to convert into protochondrocytes in vitro, aiming at activating the ASCs to convert into chondrocytes as soon as possible by fully utilizing limited time, the inventor creatively invents that the ASCs are only activated in vitro while the original activity of the ASCs is ensured, the ASCs are stimulated to an activated state, the process of converting towards a chondrocyte direction is ensured, the time point and the strength of activation are adjusted, and the ASCs in the activated state are injected into a diseased joint cavity to be continuously converted into the chondrocytes according to the original plan. This saves time and no longer emphasizes the use of three-dimensional models and a more difficult to control augmented growth environment, and the resulting chondrocytes also reduce the corresponding rejection response.
Detailed Description
It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
An in vitro method for activating the conversion of adipose stem cells into protochondrocytes, adipose tissue to be treated according to the present invention may be obtained from a patient or an immunologically acceptable donor, the adipose tissue is isolated from a fat sample, and the activated adipose tissue is cultured. An "immunologically acceptable donor" is a human having tissue, which includes adipose tissue. Firstly, washing adipose tissues by using a buffer solution to remove residual blood and tissue fragments, in the embodiment, washing by using a D-Hanks buffer solution, cutting the washed adipose tissues into small pieces, digesting in a shaking box for 20-60 min, then standing for layering, and absorbing upper-layer adipocyte liquid; placing the adipocyte liquid in a box body at the temperature of 0-5 ℃ for culturing for 1-2 hours, finding that the activity of the adipocyte liquid can be increased by utilizing the earlier stage of culturing in the box body at the temperature of 0-5 ℃ for 1-2 hours, sealing, centrifuging, removing supernatant liquid, and preparing adipose-derived stem cell suspension; placing the adipose-derived stem cell suspension in a cell activation medium for activation culture for 10-20 hours so as to obtain preliminarily expanded adipose-derived stem cells; although any cell activation medium may be used in the method of the present invention, it is preferable to culture the cells for 10 to 20 hours using a serum-free lymphocyte culture medium supplemented with interleukin-2 and saproline, so as to obtain preliminarily expanded adipose-derived stem cells; in another embodiment, the cell activation medium may further comprise mammalian serum, wherein the mammalian serum is preferably mammalian fetal serum, such as fetal bovine serum, and the amount of the mammalian serum is about 10% or 15%. The most basic nutrients for activating cells in vitro are suitable media. These media generally consist of physiological saline, amino acids, vitamins and other compounds which can be utilized directly by the cells, preferably RPMI1640 medium or serum-free medium AIM-V. The culture medium can be supplemented with mammalian immune serum, such as embryonic bovine immune serum, placing the adipose-derived stem cells in at least one cell culture medium, adding activating agent, and culturing for 12-15 hr to obtain activated adipose-derived stem cells; any cell culture medium may be used in the methods of the invention, but preferably a cell culture medium supplemented with a calcium ionophore selected from a23187 or ionomycin; in another embodiment the activating agent may also be selected from adenoviruses. Washing the activated blood cells with normal saline for at least one time, preferably washing with normal saline for two times in the embodiment of the invention, then adding enzyme liquid for digestion treatment, and culturing for three to six generations after the fat stem cells grow to 80-90% and are fused, preferably for five generations in the embodiment; naturally placing the culture solution after passage for 3-5 hours to obtain P5 generation ASCs with low immunogenicity of the micelle, and performing induction activation in vitro under the action of various stimulating factors to enable the cells to be in an activated state. Preparing a DMEM medium, wherein the proportion of the DMEM medium is 1% fetal calf serum, 10ng/ml TGF-beta, 100ng/ml BMP-6, 6.25 mu g/ml insulin, 0.1 mu mol/L dexamethasone, 6.25 mu g/ml transferrin and 50 mu mol/L ascorbic acid phosphate; placing the adipose-derived stem cells forming the micelles in a DMEM culture medium for culturing; injecting the adipose-derived stem cells cultured for 7-9 days into joint cavity to transform into protochondrocytes. Experiments prove that the relation between the culture days and the activation states of the ASCs is that the ASCs are in the optimal articular cavity injection period after being cultured for about 8 days (7-9 days), and the ASCs not only keep the original activity and homing property, but also can be accurately transformed to the original chondrocytes. Between 6 days, the ASCs were viable but had a low chance of conversion to primary chondrocytes. If more than 9 days, the activity of ASCs is reduced, and the homing property is reduced, resulting in low conversion into protochondrocytes. The optimal activation time was therefore determined to be around 8 days.
The inventor creatively invents that the ASCs are only activated in vitro while the original activity is ensured, the ASCs are stimulated to be in an activated state, the process of converting towards a cartilage cell direction is ensured, the time point and the intensity of activation are adjusted, and the ASCs in the activated state are injected into a diseased joint cavity to be continuously converted into the cartilage cell according to the original plan. This saves time without emphasizing the use of a three-dimensional model and a more difficult to control augmented growth environment, and the resulting chondrocytes also reduce the corresponding rejection response.
The incubation temperature is for example between 30 and 42 ℃. In other embodiments, between 32 and 40 ℃, or between 37 and 38 ℃, or any range contained therein. One of ordinary skill in the art will recognize that other ranges of time and temperature within these explicit ranges are contemplated and are within the present disclosure. Or any range subsumed therein. One of ordinary skill in the art will recognize that other ranges of time and temperature within these explicit ranges are contemplated and are within the present disclosure. Or any range subsumed therein. One of ordinary skill in the art will recognize that other ranges of time and temperature within these explicit ranges are contemplated and are within the present disclosure.
In the preparation of the adipose-containing stem cells related to the invention, the inventor finds that after calcium ionophore or adenovirus is added into the adipose-containing stem cells, the activated adipose-containing stem cells can stimulate the secretion amount of exosomes after entering a human body, which is 2-3 times of the secretion amount of other culture modes. The adipose-derived stem cells can be activated by contacting them with an activating agent, and the activated adipose-derived stem cells have a functional level that stimulates secretion, and the secretion amount of the exosomes is further increased by further subculturing.
Calcium ionophore is a specific metal ion species that can freely pass through lipid bilayers and soluble lipids. There are two types of ionophores: ions formed by the carrier or the channel, like adenovirus is used as the carrier, a cage-shaped structure is formed around the special ions, and the ions can freely diffuse in a hydrophobic region of a hydrophobic bilayer; channel-forming ions, such as gram-positive bacteria, form continuous liquid polar surfaces in a bilayer molecular membrane, allowing ions to diffuse through. In addition, suitable ionophores for the present invention include calcium ionophore A23187 (calcimycin), sodium salts, magnesium salts, and the like, in addition to the carriers described above. Such as calcium ionophore a23187, which are capable of responding to changes in PH gradients to concentrate calcium ions. Calcium ionophore a23187 has an acidic carboxyl group which exchanges with other cations throughout the biofilm and returns to the other end of the membrane when ion exchange is complete. The effective concentration of the ionophore is 0.05-0.5 ug/ml, and the effective concentration of the ionophore is the effective concentration for activating the adipose-derived stem cells.
While embodiments of the present invention have been described, the present invention is not limited to the above-described embodiments, which are intended to be illustrative rather than limiting, and many modifications may be made by those skilled in the art without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (9)
1. A method for activating the transformation of adipose-derived stem cells into protochondrocytes in vitro, which comprises the following steps:
preparing a DMEM medium, wherein the proportion of the DMEM medium is 1% fetal calf serum, 10ng/ml TGF-beta, 100ng/ml BMP-6, 6.25 mu g/ml insulin, 0.1 mu mol/L dexamethasone, 6.25 mu g/ml transferrin and 50 mu mol/L ascorbic acid phosphate;
placing the adipose-derived stem cells forming the micelles in a DMEM culture medium for culturing;
injecting the adipose-derived stem cells cultured for 7-9 days into joint cavity to transform into protochondrocytes.
2. The method of claim 1, wherein: the preparation steps of the adipose-derived stem cells are as follows:
cleaning adipose tissues by using a buffer solution to remove residual blood and tissue fragments, cutting the cleaned adipose tissues into small pieces, digesting the small pieces in a shaking box for 20-60 min, standing the small pieces until the small pieces are layered, sucking upper layer adipose cell fluid, placing the adipose cell fluid in a box body at the temperature of 0-5 ℃ for culturing for 1-2 hours, sealing and centrifugally separating the box body, and removing supernatant to prepare adipose stem cell suspension;
placing the adipose-derived stem cell suspension in a cell activation medium for activation culture for 10-20 hours so as to obtain preliminarily expanded adipose-derived stem cells;
placing the adipose-derived stem cells into at least one cell culture medium and adding an activating reagent to perform adipose-derived stem cell suspension culture for 12-15 hours so as to obtain activated adipose-derived stem cells;
taking out the activated adipose-derived stem cells from the culture medium, adding normal saline, cleaning, adding enzyme solution for digestion, and culturing for three to six generations after the adipose-derived stem cells grow to 80-90% and are fused;
and naturally placing the culture solution after passage for 3-5 hours to obtain the micelle adipose-derived stem cells.
3. The method of claim 1, wherein: the adipose-derived stem cells cultured for 8 days are injected into the joint cavity and transformed into the original chondrocytes.
4. The method of claim 2, wherein: after the adipose-derived stem cells grow to 80% -90% and fuse, the cells are cultured for five generations.
5. The method of claim 2, wherein: the cell activation culture medium is a serum-free lymphocyte culture medium added with interleukin-2 and saperin.
6. The method of claim 2, wherein: the cell activation medium is supplemented with mammalian serum.
7. The method of claim 7, wherein: the mammalian serum is mammalian fetal serum.
8. The method of claim 2, wherein: the activating agent is a calcium ionophore.
9. The method of claim 9, wherein: the calcium ionophore is selected from A23187 or ionomycin.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911143935.4A CN111518751A (en) | 2019-11-20 | 2019-11-20 | Method for in vitro activating adipose-derived stem cells to convert adipose-derived stem cells into protochondrocytic cells |
| PCT/CN2019/130828 WO2021098025A1 (en) | 2019-11-20 | 2019-12-31 | Method for in-vitro activation of adipose stem cells to transform into proto-chondrocytes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911143935.4A CN111518751A (en) | 2019-11-20 | 2019-11-20 | Method for in vitro activating adipose-derived stem cells to convert adipose-derived stem cells into protochondrocytic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111518751A true CN111518751A (en) | 2020-08-11 |
Family
ID=71910318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911143935.4A Withdrawn CN111518751A (en) | 2019-11-20 | 2019-11-20 | Method for in vitro activating adipose-derived stem cells to convert adipose-derived stem cells into protochondrocytic cells |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN111518751A (en) |
| WO (1) | WO2021098025A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111996162A (en) * | 2020-09-08 | 2020-11-27 | 依科赛生物科技（太仓）有限公司 | Chondrogenic differentiation medium and application thereof |
| CN112430570A (en) * | 2020-11-25 | 2021-03-02 | 北京欣颂生物科技有限公司 | Use of adipose-derived stem cells edited by gene editing technology for improving differentiation efficiency |
| CN113201487A (en) * | 2021-07-06 | 2021-08-03 | 广东先康达生物科技有限公司 | Chondroblast culture medium and chondroblast culture method |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106047804A (en) * | 2016-05-30 | 2016-10-26 | 浙江大学 | Purifying method of adipose-derived stem cells and application of stem cells on osteogenic induction and chondrogenesis |
| CN106350483A (en) * | 2016-10-14 | 2017-01-25 | 中卫华医（北京）生物科技有限公司 | Culture method for inducing adipose tissue-derived stromal cells to differentiate to chondrocyte |
| CN107338218A (en) * | 2017-07-28 | 2017-11-10 | 中国人民解放军总医院第附属医院 | Derivant and method of a kind of induced lipolysis stem cell to Chondrocyte Differentiation |
| CN108251365A (en) * | 2016-12-28 | 2018-07-06 | 华南生物医药研究院 | Immune cell media system |
| CN108410803A (en) * | 2018-03-28 | 2018-08-17 | 南京千年健干细胞基因工程有限公司 | A kind of induced lipolysis stem cell at cartilage differentiation cultural method and culture solution |
| CN109468270A (en) * | 2018-12-20 | 2019-03-15 | 河南省银丰生物工程技术有限公司 | A kind of fat stem cell and umbilical cord mesenchymal stem cells at chondrocyte induction method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007089798A2 (en) * | 2006-01-30 | 2007-08-09 | University Of Virginia Patent Foundation | Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof |
-
2019
- 2019-11-20 CN CN201911143935.4A patent/CN111518751A/en not_active Withdrawn
- 2019-12-31 WO PCT/CN2019/130828 patent/WO2021098025A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106047804A (en) * | 2016-05-30 | 2016-10-26 | 浙江大学 | Purifying method of adipose-derived stem cells and application of stem cells on osteogenic induction and chondrogenesis |
| CN106350483A (en) * | 2016-10-14 | 2017-01-25 | 中卫华医（北京）生物科技有限公司 | Culture method for inducing adipose tissue-derived stromal cells to differentiate to chondrocyte |
| CN108251365A (en) * | 2016-12-28 | 2018-07-06 | 华南生物医药研究院 | Immune cell media system |
| CN107338218A (en) * | 2017-07-28 | 2017-11-10 | 中国人民解放军总医院第附属医院 | Derivant and method of a kind of induced lipolysis stem cell to Chondrocyte Differentiation |
| CN108410803A (en) * | 2018-03-28 | 2018-08-17 | 南京千年健干细胞基因工程有限公司 | A kind of induced lipolysis stem cell at cartilage differentiation cultural method and culture solution |
| CN109468270A (en) * | 2018-12-20 | 2019-03-15 | 河南省银丰生物工程技术有限公司 | A kind of fat stem cell and umbilical cord mesenchymal stem cells at chondrocyte induction method |
Non-Patent Citations (2)
| Title |
|---|
| 朱江: "脂肪干细胞联合富血小板血浆修复关节软骨研究进展", 《医学综述》 * |
| 陈慧: "脂肪干细胞应用于软骨缺损修复的研究新进展", 《口腔医学研究》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111996162A (en) * | 2020-09-08 | 2020-11-27 | 依科赛生物科技（太仓）有限公司 | Chondrogenic differentiation medium and application thereof |
| CN111996162B (en) * | 2020-09-08 | 2022-03-04 | 依科赛生物科技（太仓）有限公司 | Chondrogenic differentiation medium and application thereof |
| CN112430570A (en) * | 2020-11-25 | 2021-03-02 | 北京欣颂生物科技有限公司 | Use of adipose-derived stem cells edited by gene editing technology for improving differentiation efficiency |
| CN113201487A (en) * | 2021-07-06 | 2021-08-03 | 广东先康达生物科技有限公司 | Chondroblast culture medium and chondroblast culture method |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021098025A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Parker et al. | Adipose-derived stem cells for the regeneration of damaged tissues | |
| CN101412985B (en) | Serum-free medium for in vitro cultivation and amplification of mesenchymal stem cells | |
| DK1265986T3 (en) | METHOD FOR IN VITRO PRODUCTION OF dimensional, vital cartilage or bone | |
| Shen et al. | Implications of adipose-derived stromal cells in a 3D culture system for osteogenic differentiation: an in vitro and in vivo investigation | |
| CN111518751A (en) | Method for in vitro activating adipose-derived stem cells to convert adipose-derived stem cells into protochondrocytic cells | |
| CN103223194A (en) | Cartilage graft for cartilage injury repair and preparation method thereof | |
| CN110478528B (en) | Preparation method and application of novel tissue repair promoting material | |
| CN104673745A (en) | Isolated culture method of porcine fat stem cells | |
| CN107557331A (en) | A kind of method for separating and cultivating human adipose-derived stem cell | |
| CN107376025B (en) | Preparation method and application of cell-scaffold composite material for cartilage injury repair | |
| CN104250655A (en) | BMP(bone morphogenetic protein)-2/VEGF(vascular endothelial growth factor)165 double gene modified bone marrow mesenchymal stem cells and preparation method thereof | |
| Frontini López et al. | Adipose-derived mesenchymal stem/stromal cells: from the lab bench to the basic concepts for clinical translation | |
| CN110846274A (en) | Preparation method of compound cell preparation applied to osteoarthritis and use method of compound cell preparation | |
| CN100564518C (en) | Placenta amnion cell extract and induce application in the differentiation at mescenchymal stem cell | |
| CN109797136A (en) | A kind of isolated culture method of human adipose mesenchymal stem cells | |
| CN112190596A (en) | Mesenchymal stem cell preparation for treating arthritis and preparation method thereof | |
| CN103382458A (en) | Culture solution and method for inducing mesenchymal stem cells to differentiate into glomerular mesangial cells | |
| CN109402049A (en) | A kind of preparation method for the tissue engineering fat stem cell lamella with cartilage differentiation potential can be used for cartilage damage reparation | |
| EP4070824A1 (en) | Marine scaffolds for human tissue generation | |
| da Costa Gonçalves et al. | Dynamic culture improves MSC adhesion on freeze-dried bone as a scaffold for bone engineering | |
| JP6525282B2 (en) | Fat-derived stem cell sheet having osteogenic potential and method for producing the same | |
| Maxson et al. | Synergistic effects of conditioned media and hydrostatic pressure on the differentiation of mesenchymal stem cells | |
| CN111000791A (en) | Preparation method of facial mask containing adipose-derived stem cell exosomes | |
| CN111714698A (en) | Biological gel composition containing cells, preparation method and application thereof | |
| JP4646600B2 (en) | Method for culturing mesenchymal stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200811 |
|
| WW01 | Invention patent application withdrawn after publication |